α(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking

Biol Psychiatry. 2011 Oct 15;70(8):712-719. doi: 10.1016/j.biopsych.2011.06.010. Epub 2011 Jul 23.

Abstract

Background: Drug-associated cues can elicit stress-like responses in addicted individuals, indicating that cue- and stress-induced drug relapse may share some neural mechanisms. It is unknown whether α(2) adrenergic receptor agonists, which are known to attenuate stress-induced reinstatement of drug seeking in rats, also reduce cue-induced reinstatement.

Methods: Rats were tested for reinstatement of drug seeking following cocaine self-administration and extinction. We first evaluated the effects of clonidine, an agonist at α(2) and imidazoline-1 (I(1)) receptors, on relapse to cocaine seeking. To explore possible mechanisms of clonidine's effects, we then tested more specific α(2) or I(1) agonists, postsynaptic adrenergic receptor (α(1) and β) antagonists, and corticotropin-releasing factor receptor-1 antagonists.

Results: We found that clonidine, and the more selective α(2) agonists UK-14,304 and guanfacine, decreased cue-induced reinstatement of cocaine seeking. The specific I(1) receptor agonist moxonidine reduced cue-induced as well as cocaine-induced reinstatement. Clonidine or moxonidine effects on cue-induced reinstatement were reversed by the selective α(2) receptor antagonist RS-79948, indicating a role for α(2) receptors. Prazosin and propranolol, antagonists at the α(1) and β receptor, respectively, reduced cue-induced reinstatement only when administered in combination. Finally, the corticotropin-releasing factor receptor-1 antagonist CP-154,526 reduced cue-induced reinstatement, as previously observed for stress-induced reinstatement, indicating possible overlap between stress and cue mechanisms.

Conclusions: These results indicate that α(2) and I(1) receptor agonists are novel therapeutic options for prevention of cue-induced cocaine relapse. Given that α(2) receptor stimulation is associated with sedation in humans, the I(1) agonist moxonidine seems to have substantial potential for treating addictive disorders.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists / pharmacology
  • Adrenergic alpha-2 Receptor Agonists / pharmacology*
  • Adrenergic alpha-2 Receptor Antagonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Brimonidine Tartrate
  • Clonidine / antagonists & inhibitors
  • Clonidine / pharmacology
  • Cocaine / administration & dosage
  • Cocaine / antagonists & inhibitors
  • Cocaine / pharmacology*
  • Cues
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug-Seeking Behavior / drug effects*
  • Extinction, Psychological / drug effects
  • Guanfacine / pharmacology
  • Imidazoles / antagonists & inhibitors
  • Imidazoles / pharmacology
  • Imidazoline Receptors / agonists*
  • Isoquinolines / pharmacology
  • Male
  • Motor Activity / drug effects
  • Naphthyridines / pharmacology
  • Prazosin / pharmacology
  • Propranolol / pharmacology
  • Pyrimidines / pharmacology
  • Pyrroles / pharmacology
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Reinforcement, Psychology
  • Self Administration / psychology

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Adrenergic beta-Antagonists
  • CP 154526
  • Imidazoles
  • Imidazoline Receptors
  • Isoquinolines
  • Naphthyridines
  • Pyrimidines
  • Pyrroles
  • Quinoxalines
  • RS 79948-197
  • imidazoline I1 receptors
  • Guanfacine
  • Brimonidine Tartrate
  • Propranolol
  • moxonidine
  • Cocaine
  • Clonidine
  • Prazosin